Indietro

Sanofi ADR

Ticker: SNY ISIN: US80105N1054
Aggiungi al portafoglio Analisi del portafoglio in 2min
Stock Large-cap
Capitalizzazione
116,71 Mld $
P/E
15,69
Forward P/E
9,78
Profit margin
19,84%
Revenue growth QoQ
-7,00%
Div. yield
0,00%
Beta
0,40
45,69 $ -0,35%
Prezzo al 2026-08-24 · NASDAQ

Performance per periodo

Rendimenti cumulativi
1 Month +3,84%
6 Months +1,93%
1 Year -3,80%
5 Years +1,81% p.a.+9,37%
10 Years +5,89% p.a.+77,18%
Since inception +5,62% p.a.+274,81%
Rendimenti per anno
YTD -0,49%
2025 +4,93%
2024 +1,09%
2023 +6,71%
2022 +0,47%
2021 +7,00%

Key stats

Market cap
116,71 Mld
P/E
15,69
Dividend yield
0,00%
Beta
0,40
52-week range
44.62 - 57.57
50-day MA
49,52
200-day MA
49,86
Section 1

Business overview

Company profile data from fundamentals.

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sector Healthcare
Industry Drug Manufacturers - General
Country France
Exchange NASDAQ
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 8,84%
ROA 4,61%
Profit margin 19,84%
Operating margin 28,73%
PEG ratio 0,73
Revenue/share TTM 18,66
Revenue TTM 45,93 Mld
EBITDA 12,33 Mld
Gross profit TTM 33,07 Mld
Beta 0,40

Valuation

Trailing P/E 15,69
Forward P/E 9,78
P/B 1,36
P/S 2,54
EV/EBITDA 8,35
EV/Revenue 2,30
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 4,56
Quarterly earnings growth 2,40%
Revenue TTM 45,93 Mld
Reported quarters 65
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 0,00%
Forward annual div. yield 4,56%
Dividend per share 0,0000
Payout ratio 51,46%
Ex-dividend date 2025-05-09
Split factor 5:1
Last split date 2013-09-30
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 58,68 $
Analyst rating 4.1818

Ownership & short interest

Shares outstanding 2,42 Mld
Shares float 1,10 Mld
Institutional ownership 9,89%
Insider ownership 0,10%
Short ratio 2,76
Short % of float 0,35%

Details

Instrument metadata and source update timestamps.

Symbol SNY
Name Sanofi ADR
Asset type STOCK
Exchange NASDAQ
Currency USD
ISIN US80105N1054
Country USA
Code + exchange SNY.NASDAQ
Last price date 2026-01-06
Fundamentals updated 2026-01-07

Le informazioni fornite su questa piattaforma hanno solo scopo informativo e non devono essere considerate consulenza finanziaria o di investimento. Insightfolio non fornisce consulenza d'investimento, raccomandazioni personalizzate o indicazioni relative all'acquisto, alla detenzione o alla vendita di strumenti finanziari. Gli strumenti e i contenuti sono destinati esclusivamente a finalita educative e non sono adattati alle circostanze individuali, alle esigenze finanziarie o agli obiettivi personali.

Insightfolio non si assume alcuna responsabilita per l'accuratezza, la completezza o l'affidabilita delle informazioni presentate. Gli utenti sono gli unici responsabili della verifica delle informazioni e dell'assunzione di decisioni indipendenti basate sulla propria ricerca e su un'attenta valutazione. L'uso della piattaforma non deve sostituire la consulenza di professionisti finanziari qualificati.

Gli investimenti comportano rischi. Gli utenti devono essere consapevoli che il valore degli investimenti puo variare e che i rendimenti passati non sono indicativi di risultati futuri. Le decisioni di investimento devono basarsi sugli obiettivi finanziari personali, sulla tolleranza al rischio e su una valutazione indipendente delle informazioni rilevanti.

Insightfolio non approva ne garantisce l'idoneita di alcun prodotto finanziario, titolo o strategia specifica. Eventuali proiezioni, previsioni o scenari ipotetici presentati sulla piattaforma hanno solo scopo illustrativo e non costituiscono garanzia di risultati futuri.

Accedendo ai servizi, alle informazioni o ai contenuti offerti da Insightfolio, gli utenti riconoscono e accettano i presenti termini di esclusione di responsabilita. Se non accetti questi termini, ti invitiamo a non utilizzare la piattaforma.

Instrument logos provided by Elbstream.